Real-world Outcomes of Durvalumab Consolidation in Elderly Patients With Unresectable NSCLC Following CCRT With Daily Low-dose Carboplatin
In real-world settings, durvalumab consolidation therapy following CCRT with daily low-dose carboplatin does not appear to provide clinical benefits in terms of PFS or OS for elderly patients with unresectable, locally advanced NSCLC.
Authors
- Naoko Morishita
- Yuki Hosono (ORCID: https://orcid.org/0000-0001-9993-6789)
- Takafumi Yanase
- So Takata (ORCID: https://orcid.org/0000-0002-8071-1077)
- Hidetaka Tanabe
- Hidekazu Suzuki (ORCID: https://orcid.org/0000-0002-1556-1199)
- M. Yokoyama (ORCID: https://orcid.org/0000-0003-2742-0251)
- Shingo Satoh
- Keijiro Yamauchi
- Riiko Komuta
Institutions
- Osaka Prefectural Medical Center (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2024-12-30
- DOI
- https://doi.org/10.21873/anticanres.17425
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00